Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Genetics Generation Advancement's 10-Year RORE % for the quarter that ended in Mar. 2026 was 44.69%.
ROCO:4160's 10-Year RORE % is ranked better than 90.83% of 120
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.425
vs ROCO:4160: 44.69
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Genetics Generation Advancement 10-Year RORE % Related Terms
Genetics Generation Advancement 10-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4160 vs TMO, DHR, IDXX: 10-Year RORE % Comparison
For the Diagnostics & Research subindustry, Genetics Generation Advancement's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetics Generation Advancement 10-Year RORE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetics Generation Advancement's 10-Year RORE % distribution charts can be found below:
* The bar in red indicates where Genetics Generation Advancement's 10-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 10-year before.
Genetics Generation Advancement (ROCO:4160) has a 10-Year RORE % of 44.69 as of Mar. 2026. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Genetics Generation Advancement and its competitors. According to the industry distribution chart, Genetics Generation Advancement ranks #11 out of 120 companies in the Medical Diagnostics & Research industry, placing it in the top 9.2%.
Is Genetics Generation Advancement's 10-Year RORE % too high?
Genetics Generation Advancement's current 10-Year RORE % is 44.69. The Medical Diagnostics & Research industry median 10-Year RORE % is 0.43. Genetics Generation Advancement's value of 44.69 is 10415.3% above this industry median. Based on the distribution chart, Genetics Generation Advancement ranks #11 out of 120 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Genetics Generation Advancement has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genetics Generation Advancement's 10-Year RORE % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetics Generation Advancement ranks #11 out of 120 companies for 10-Year RORE %. This places Genetics Generation Advancement in the top 9% of its industry — outperforming the majority of peers. The industry median 10-Year RORE % is 0.43. Genetics Generation Advancement's value of 44.69 is 10415.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Medical Diagnostics & Research company?
The median 10-Year RORE % among Medical Diagnostics & Research companies is 0.43, based on 120 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genetics Generation Advancement's current 10-Year RORE % of 44.69 is 10415.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Genetics Generation Advancement and its competitors. For the Medical Diagnostics & Research industry, the median 10-Year RORE % is 0.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetics Generation Advancement's current 10-Year RORE % is 44.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetics Generation Advancement stock overvalued right now?
Based on GuruFocus' analysis, Genetics Generation Advancement (ROCO:4160) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$53.60, compared to a current price of NT$39.95 — trading 25.5% below its estimated fair value. The current 10-Year RORE % is 44.69 and 10415.3% above the Medical Diagnostics & Research industry median of 0.43. Genetics Generation Advancement's overall GF Score™ is 69/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Genetics Generation Advancement (ROCO:4160), the current 10-Year RORE % is 44.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genetics Generation Advancement (ROCO:4160) Overvalued in 2026?
Based on GuruFocus' analysis, Genetics Generation Advancement stock appears to be undervalued.
The current stock price of NT$39.95 is trading 25.5% below its estimated GF Value™ of NT$53.60.
GuruFocus considers Genetics Generation Advancement to be Modestly Undervalued.
Key valuation signals for ROCO:4160:
10-Year RORE %: 44.69
GF Value™: NT$53.60 vs. price of NT$39.95 (25.5% below fair value)
Industry Position: 10415.3% above the Medical Diagnostics & Research median (#11 of 120)
No single metric tells the full story. See the ROCO:4160 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genetics Generation Advancement Corp is a Taiwan based company specialized in genetic testing and scientific information. It is engaged in providing services for the detection of genetic defects and prevention in newborns. Their main services include amniotic fluid chromosome chip screening, pre-implantation genetic diagnosis, and Molecular DNA testing diagnostics. The company is focused on the majority of areas of maternal precision medicine, pediatric disease diagnosis, drug-associated diagnosis, non-invasive cancer detection, and precise health management. The business units of the company are the Genetic Testing Unit and Informatics business unit.
69GF Score
Get the complete analysis for ROCO:4160
10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4160 has been successfully added to your 
